NZ623454A - Pharmaceutical composition for the treatment of heart diseases - Google Patents

Pharmaceutical composition for the treatment of heart diseases

Info

Publication number
NZ623454A
NZ623454A NZ623454A NZ62345410A NZ623454A NZ 623454 A NZ623454 A NZ 623454A NZ 623454 A NZ623454 A NZ 623454A NZ 62345410 A NZ62345410 A NZ 62345410A NZ 623454 A NZ623454 A NZ 623454A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
treatment
fog2
fog1
mesp1
Prior art date
Application number
NZ623454A
Other languages
English (en)
Inventor
Christian Homsy
Roland Gordon-Beresford
Vinciane Gaussin
Original Assignee
Cardio3 Biosciences Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio3 Biosciences Sa filed Critical Cardio3 Biosciences Sa
Publication of NZ623454A publication Critical patent/NZ623454A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ623454A 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases NZ623454A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2009056197 2009-05-20
NZ596162A NZ596162A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases

Publications (1)

Publication Number Publication Date
NZ623454A true NZ623454A (en) 2015-12-24

Family

ID=41323568

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ623454A NZ623454A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases
NZ596162A NZ596162A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ596162A NZ596162A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases

Country Status (15)

Country Link
US (2) US9446076B2 (enExample)
JP (1) JP6029468B2 (enExample)
KR (1) KR101689415B1 (enExample)
CN (2) CN107028980A (enExample)
AU (1) AU2010251151B2 (enExample)
BR (1) BRPI1012116A2 (enExample)
CA (1) CA2762584A1 (enExample)
ES (1) ES2541212T3 (enExample)
IL (1) IL216399A0 (enExample)
MX (1) MX2011012183A (enExample)
NZ (2) NZ623454A (enExample)
RU (1) RU2595801C2 (enExample)
SG (1) SG175880A1 (enExample)
TW (1) TWI492707B (enExample)
WO (1) WO2010133686A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173118B2 (en) 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2013007284A1 (en) * 2011-07-08 2013-01-17 Mikael Sigvardsson A method for enriching mesenchymal stem cells and applications thereof
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
WO2013163479A1 (en) * 2012-04-25 2013-10-31 General Istrazivanja D.O.O. Methods and compositions for treating and diagnosing acute myocardial infarction
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
BR112015030374A2 (pt) * 2013-06-28 2017-07-25 Otsuka Pharma Factory Inc solução contendo trealose e dextrana para transplante de células mamíferas
CN103667440A (zh) * 2013-09-05 2014-03-26 谢小冬 Gata4基因snp位点的用途
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
WO2016141234A1 (en) 2015-03-03 2016-09-09 Regents Of The University Of Minnesota Etv2 and uses thereof
US10874092B2 (en) 2015-06-30 2020-12-29 Regents Of The University Of Minnesota Humanized skeletal muscle
CN108472318A (zh) * 2015-06-30 2018-08-31 明尼苏达大学校董会 人源化心脏肌肉
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
WO2017064688A1 (en) * 2015-10-15 2017-04-20 Cells For Cells, S.P.A. Neurite regeneration therapy based on exosomes derived from menstrual stem cells
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
CN106619718A (zh) * 2016-10-18 2017-05-10 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN106474456A (zh) * 2016-10-18 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CN108070645A (zh) * 2016-11-11 2018-05-25 中国科学院上海生命科学研究院 Stx-t在预防和/或治疗贫血或其相关疾病的应用
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
CN109497038A (zh) * 2017-09-14 2019-03-22 青岛瑞思德生物科技有限公司 一种脂肪保存液及其制备方法
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
BR112020013238A2 (pt) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
CN108244096B (zh) * 2018-01-10 2019-01-04 暨赛再生医学科技有限公司 一种长期保存过表达vegf的血管内皮祖细胞的保存液
CN108379662A (zh) * 2018-02-08 2018-08-10 深圳大图科创技术开发有限公司 一种干细胞在心脏移植模型的应用
CN108546757B (zh) * 2018-03-05 2021-09-07 上海长海医院 Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
CN110812369A (zh) * 2018-08-10 2020-02-21 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
CN109266604B (zh) * 2018-10-10 2020-11-10 浙江神雁精准医疗科技有限公司 包含干细胞活性物质的组合物及其制备方法
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CN109769799A (zh) * 2019-03-20 2019-05-21 江苏瑞思坦生物科技有限公司 一种人脂肪组织保存液及其制备方法
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
EP4015623A1 (en) * 2020-12-17 2022-06-22 Universite De Montpellier Pre-treatment of msc with ppar beta/delta agonist for treatment of ischemia-reperfusion injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6921633B2 (en) * 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
KR100674783B1 (ko) * 2003-12-09 2007-01-25 (주)안트로젠 세포 이식을 위한 세포의 생산 방법
US8173118B2 (en) 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
WO2006080434A1 (ja) * 2005-01-27 2006-08-03 Japan Health Sciences Foundation 間葉系幹細胞を含む細胞シート
CA2603857A1 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US8074465B2 (en) * 2005-09-12 2011-12-13 Genzyme Corporation Thermally insulated transport container for cell-based products and related methods
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
AU2008204541B2 (en) 2007-01-09 2014-07-10 Lead Pharma Cel Models Ip B.V. Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
EP2131868A4 (en) * 2007-03-07 2011-04-13 Mayo Foundation HEART-SPECIFIC STORAGE CELLS
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
FR2917381B1 (fr) 2007-06-15 2009-10-16 Ceva Sante Animale Sa Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique
KR101995016B1 (ko) * 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
WO2009121002A1 (en) * 2008-03-27 2009-10-01 Biolife Solutions, Inc. Materials and methods for hypothermic collection of whole blood
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
BE1018733A3 (fr) 2009-04-29 2011-07-05 Cardio3 Biosciences Sa Dispositif pour la delivrance d'un agent therapeutique.

Also Published As

Publication number Publication date
IL216399A0 (en) 2012-01-31
AU2010251151B2 (en) 2015-08-20
SG175880A1 (en) 2011-12-29
CN102438636A (zh) 2012-05-02
JP6029468B2 (ja) 2016-11-24
KR101689415B1 (ko) 2016-12-23
TWI492707B (zh) 2015-07-21
JP2012527432A (ja) 2012-11-08
WO2010133686A8 (en) 2012-03-08
CN107028980A (zh) 2017-08-11
US20160279168A1 (en) 2016-09-29
ES2541212T3 (es) 2015-07-16
MX2011012183A (es) 2012-03-06
WO2010133686A1 (en) 2010-11-25
TW201108935A (en) 2011-03-16
AU2010251151A1 (en) 2011-11-24
US9446076B2 (en) 2016-09-20
RU2011145370A (ru) 2013-06-27
US10086016B2 (en) 2018-10-02
BRPI1012116A2 (pt) 2016-03-15
KR20120046107A (ko) 2012-05-09
NZ596162A (en) 2014-06-27
CA2762584A1 (en) 2010-11-25
HK1163500A1 (en) 2012-09-14
US20120128638A1 (en) 2012-05-24
RU2595801C2 (ru) 2016-08-27

Similar Documents

Publication Publication Date Title
NZ596162A (en) Pharmaceutical composition for the treatment of heart diseases
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
MX340185B (es) Células precursoras cd27 1 derivadas de médula ósea para reparación cardíaca.
NZ603913A (en) Method of engrafting cells from solid tissues
WO2011064669A3 (en) Adherent cells from placenta and use of same in disease treatment
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2010134007A3 (en) Low-level energy laser therapy
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
WO2010082787A2 (ko) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
WO2013056049A3 (en) Tubular prostheses
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
Wang et al. The role of renin-angiotensin system in cellular differentiation: implications in pancreatic islet cell development and islet transplantation
MX2013008374A (es) Apolipoproteina a-iv como un peptido antidiabetico.
BR112013009043A2 (pt) composto, uso de um composto, e, método para tratar uma doença
Wang et al. Loganin epigenetically rescues mitochondrial complex III dysfunction via DNMT1-UQCRC1 demethylation to halt cardiac remodeling after myocardial infarction
WO2014072720A3 (en) Cell differentiation
MY163107A (en) Pharmaceutical composition for the treatment of bladder disorders
WO2009094340A3 (en) Omentum and use thereof
AU2010347212B2 (en) Cell free preparation and uses thereof
SG11201900983TA (en) Amelioration and treatment of chronic lung disease using pluripotent stem cells
JP2016216365A (ja) 皮膚を修復し活性化するための医薬組成物およびその製造方法
RU2009143025A (ru) Способ использования стволовых клеток в тканезаместительной терапии
TH125509A (th) การรักษาที่ใช้เซลล์ของผู้ใหญ่ที่เจริญเต็มที่ที่ถูกโปรแกรมใหม่
Fernandez-Miranda Metabolic syndrome and sedation: 2 case reports

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 MAY 2017 BY JAMES + WELLS

Effective date: 20160726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2018 BY JAMES + WELLS

Effective date: 20170516

LAPS Patent lapsed